Associated Papers
Structural basis for mTORC1 activation on the lysosomal membrane.
Cui Z et al.
Nature, 2025
MRD4U: A path to development for personalized liquid biopsy for children with central nervous system tumors.
Miller AR et al.
Bmc Cancer, 2025
Structural basis for growth factor and nutrient signal integration on the lysosomal membrane by mTORC1.
Cui Z et al.
Biorxiv : the Preprint Server for Biology, 2024
L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma.
Alghamdi M et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024
Computational analysis of protein-protein interactions of cancer drivers in renal cell carcinoma.
Pei J et al.
Febs Open Bio, 2024
A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
Zhang H et al.
Bmc Medical Genomics, 2022
TSC-insensitive Rheb mutations induce oncogenic transformation through a combination of constitutively active mTORC1 signalling and proteome remodelling.
Xie J et al.
Cellular and Molecular Life Sciences : Cmls, 2021
Molecular basis for the functions of dominantly active Y35N and inactive D60K Rheb mutants in mTORC1 signaling.
Zhang C et al.
Journal of Molecular Cell Biology, 2020
Systematic analysis of the intersection of disease mutations with protein modifications.
Simpson CM et al.
Bmc Medical Genomics, 2019
Analysis of error profiles in deep next-generation sequencing data.
Ma X et al.
Genome Biology, 2019
An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
Heard JJ et al.
Bmc Cancer, 2018
Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
Li C et al.
Molecular Cancer Research : Mcr, 2017
Pan-urologic cancer genomic subtypes that transcend tissue of origin.
Chen F et al.
Nature Communications, 2017
Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth.
Wang Y et al.
Oncogene, 2017
LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.
Melloni GE et al.
Bmc Bioinformatics, 2016
Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP et al.
Oncotarget, 2015
Recent progress in the study of the Rheb family GTPases.
Heard JJ et al.
Cellular Signalling, 2014
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
Grabiner BC et al.
Cancer Discovery, 2014
Discovery and saturation analysis of cancer genes across 21 tumour types.
Lawrence MS et al.
Nature, 2014